BR112016017010A2 - Anticorpo monoclonal de fator antitecido - Google Patents

Anticorpo monoclonal de fator antitecido

Info

Publication number
BR112016017010A2
BR112016017010A2 BR112016017010A BR112016017010A BR112016017010A2 BR 112016017010 A2 BR112016017010 A2 BR 112016017010A2 BR 112016017010 A BR112016017010 A BR 112016017010A BR 112016017010 A BR112016017010 A BR 112016017010A BR 112016017010 A2 BR112016017010 A2 BR 112016017010A2
Authority
BR
Brazil
Prior art keywords
tissue factor
monoclonal antibody
factor monoclonal
antibody
relates
Prior art date
Application number
BR112016017010A
Other languages
English (en)
Inventor
Matsumura Yasuhiro
Yasunaga Masahiro
KOGA Yoshikatsu
Yamamoto Yoshiyuki
Sato Ryuta
Tsumura Ryo
Kataoka Kazunori
Nishiyama Nobuhiro
Miura Yutaka
Manabe Shino
Kato Yasuki
Original Assignee
Nat Cancer Ct
Univ Tokyo
Riken
Nanocarrier Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct, Univ Tokyo, Riken, Nanocarrier Co Ltd filed Critical Nat Cancer Ct
Publication of BR112016017010A2 publication Critical patent/BR112016017010A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPO MONOCLONAL DE FATOR ANTITECIDO. A presente invenção refere-se a um novo anticorpo contra o fator do tecido. A invenção também se refere a uma composição farmacêutica em que o anticorpo acima mencionado é usado como um fator de ligação com o alvo. O anticorpo de acordo com a presente invenção podem exercer uma capacidade de internalização nas células que expressam o fator do tecido.
BR112016017010A 2014-02-03 2015-02-03 Anticorpo monoclonal de fator antitecido BR112016017010A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014018586 2014-02-03
PCT/JP2015/052918 WO2015115656A1 (ja) 2014-02-03 2015-02-03 抗Ｔｉｓｓｕｅ Ｆａｃｔｏｒモノクローナル抗体

Publications (1)

Publication Number Publication Date
BR112016017010A2 true BR112016017010A2 (pt) 2017-10-03

Family

ID=53757221

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017010A BR112016017010A2 (pt) 2014-02-03 2015-02-03 Anticorpo monoclonal de fator antitecido

Country Status (11)

Country Link
US (1) US9920133B2 (pt)
EP (1) EP3103811A4 (pt)
JP (1) JP5957637B2 (pt)
KR (1) KR20160136279A (pt)
CN (1) CN106255703A (pt)
AU (1) AU2015211674A1 (pt)
BR (1) BR112016017010A2 (pt)
CA (1) CA2937034A1 (pt)
MX (1) MX2016009690A (pt)
TW (1) TWI655211B (pt)
WO (1) WO2015115656A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017028823A1 (zh) * 2015-08-20 2017-02-23 复旦大学 靶向于组织因子的抗体、其制备方法和用途
US10548986B2 (en) * 2016-03-02 2020-02-04 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
US10676537B2 (en) 2016-08-22 2020-06-09 Fudan University Antibody targeted to tissue factor, preparation method therefor, and use thereof
CN107446047B (zh) * 2017-09-04 2020-08-11 山西省生物研究院有限公司 一种双功能性抗组织因子人源化抗体及其制备方法
TW201922796A (zh) 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
MX2020007077A (es) * 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CA3108951A1 (en) * 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
CN115348971A (zh) 2020-03-30 2022-11-15 国立研究开发法人国立癌症研究中心 抗体-药物缀合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005328A1 (en) * 1992-08-28 1994-03-17 The Scripps Research Institute Inhibition of tumor metastasis via neutralization of tissue factor function
EP0729976A1 (en) 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
JPH09302000A (ja) 1996-05-16 1997-11-25 Chemo Sero Therapeut Res Inst 抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
AU5081401A (en) 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
US20030124117A1 (en) 2000-03-16 2003-07-03 Refino Canio J. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US20030143225A1 (en) 2001-03-08 2003-07-31 Genentech, Inc. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
EP3281956A3 (en) * 2010-06-15 2018-04-18 Genmab A/S Human antibody drug conjugates against tissue factor
CN108129554A (zh) 2010-08-10 2018-06-08 洛桑聚合联合学院 红细胞结合性治疗剂
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
JP5897422B2 (ja) 2012-07-23 2016-03-30 株式会社ニューギン 遊技機

Also Published As

Publication number Publication date
TWI655211B (zh) 2019-04-01
US20160333113A1 (en) 2016-11-17
JP5957637B2 (ja) 2016-07-27
AU2015211674A1 (en) 2016-08-04
EP3103811A4 (en) 2017-11-29
KR20160136279A (ko) 2016-11-29
CN106255703A (zh) 2016-12-21
US9920133B2 (en) 2018-03-20
EP3103811A1 (en) 2016-12-14
MX2016009690A (es) 2017-03-03
JPWO2015115656A1 (ja) 2017-03-23
TW201613980A (en) 2016-04-16
WO2015115656A1 (ja) 2015-08-06
CA2937034A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
BR112016017010A2 (pt) Anticorpo monoclonal de fator antitecido
CY1122898T1 (el) Απεκκριση πολυπεπτιδιων που περιεχουν αιμη
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112017007123A2 (pt) derivados de tetrahidroisoquinolina
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
EP3283080A4 (en) Compositions for modulating c9orf72 expression
EP3126499A4 (en) Compositions for modulating sod-1 expression
EP3055414A4 (en) Compositions for modulating c9orf72 expression
BR112016024660A2 (pt) geração de uma prescrição de agricultura.
MY165124A (en) Semifluorinated alkane compositions
EP3224712A4 (en) Support for application transparent, high available gpu computing with vm checkpointing
BR112016025470A2 (pt) ?hdl terapêutico?
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
MY182924A (en) Enzyme compositions and uses thereof
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
BR112017012515A2 (pt) membros vinculantes para c-maf humano
BR112017006552A2 (pt) composições e métodos para inibir a atividade biológica de biomoléculas solúveis
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
BR112014032764A2 (pt) composição farmacêutica contendo fimasartana e hidroclorotiazida
EP3197498A4 (en) Compositions containing ambient-temperature stable, inactivated but therapeutically active biopharmaceuticals&methods for formulation thereof
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
EP3199175A4 (en) Pharmaceutical composition for injection
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]